Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Marsoni

Showing results (61-70 of 89) with videos related to

Pageof 9
Sort By:
ESMO Open|September 29, 2020
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trialAndrea Sartore-Bianchi, Sara Lonardi, Cosimo Martino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2022
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal CancerErika Durinikova, Nicole M Reilly, Kristi Buzo, et al.
Frontiers in Oncology|July 30, 2019
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With RegorafenibAlessio Amatu, Marta Schirripa, Federica Tosi, et al.
Nature|November 30, 2017
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growthGiovanni Germano, Simona Lamba, Giuseppe Rospo, et al.
Clinical Colorectal Cancer|March 12, 2026
Consistency of Radiological Staging in Resectable Mismatch-Repair Proficient Colon Cancer: An Interobserver Agreement StudyVincenzo Nasca, Gabriele Tinè, Marta Vaiani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and OxaliplatinSabrina Arena, Giorgio Corti, Erika Durinikova, et al.
Cancer Discovery|May 16, 2012
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancerAndrea Bertotti, Giorgia Migliardi, Francesco Galimi, et al.
Cancer Discovery|May 6, 2022
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer PatientsGiovanni Crisafulli, Andrea Sartore-Bianchi, Luca Lazzari, et al.
Journal of the National Cancer Institute|August 25, 2020
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT DatabaseAnna D Wagner, Axel Grothey, Thierry Andre, et al.
Clinical Colorectal Cancer|September 13, 2020
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal CancerFederica Tosi, Andrea Sartore-Bianchi, Sara Lonardi, et al.
Pageof 9

Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
ESMO Open|September 29, 2020
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trialAndrea Sartore-Bianchi, Sara Lonardi, Cosimo Martino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2022
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal CancerErika Durinikova, Nicole M Reilly, Kristi Buzo, et al.
Frontiers in Oncology|July 30, 2019
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With RegorafenibAlessio Amatu, Marta Schirripa, Federica Tosi, et al.
Nature|November 30, 2017
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growthGiovanni Germano, Simona Lamba, Giuseppe Rospo, et al.
Clinical Colorectal Cancer|March 12, 2026
Consistency of Radiological Staging in Resectable Mismatch-Repair Proficient Colon Cancer: An Interobserver Agreement StudyVincenzo Nasca, Gabriele Tinè, Marta Vaiani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and OxaliplatinSabrina Arena, Giorgio Corti, Erika Durinikova, et al.
Cancer Discovery|May 16, 2012
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancerAndrea Bertotti, Giorgia Migliardi, Francesco Galimi, et al.
Cancer Discovery|May 6, 2022
Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer PatientsGiovanni Crisafulli, Andrea Sartore-Bianchi, Luca Lazzari, et al.
Journal of the National Cancer Institute|August 25, 2020
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT DatabaseAnna D Wagner, Axel Grothey, Thierry Andre, et al.
Clinical Colorectal Cancer|September 13, 2020
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal CancerFederica Tosi, Andrea Sartore-Bianchi, Sara Lonardi, et al.
Pageof 9